Promega Corporation has filed a patent infringement lawsuit against Aobious, Inc., aiming to safeguard its intellectual property concerning furimazine and its associated variants.
Furimazine, a vital component of Promega’s NanoLuc® luciferase technology, is covered by multiple active U.S. patents, and the company intends to put an immediate stop to unauthorized sales of this patented substrate and its derivatives.
“We are committed to defending our innovations and the groundbreaking products built upon these unique molecules,” said Poncho Meisenheimer, Vice President of Research and Development at Promega. ”
The development of furimazine substrates has been the result of years of dedication by our scientists, and we will protect these achievements for the benefit of the scientific community.”
The lawsuit, filed in the U.S. District Court for the District of Delaware, underscores Promega’s resolve to uphold its intellectual property rights and prevent the unauthorized use of its patented technology.
Since its inception in the early 1990s, Promega has been at the forefront of bioluminescence-based research tools. In 2012, the company introduced the groundbreaking NanoLuc® luciferase enzyme, designed to deliver superior performance as a luminescent reporter.
When NanoLuc® interacts with furimazine, it produces a highly efficient and bright luminescent signal, revolutionizing research in fields such as protein expression, localization, degradation, and interactions.
Furimazine substrates, including its variants hydrofurimazine and fluorofurimazine, are central to the power of NanoLuc®-based systems. Promega’s patents protect these substrates’ unique chemical structures, which are critical for generating the bright luminescence required for precise scientific studies. These substrates are protected not only in the U.S. but also in 28 other countries, further reinforcing Promega’s commitment to safeguarding its innovative work.
Read more: